Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts signal growth. Click for my CRSP update.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...